Immunotherapy in patients with autoimmune disease

Area of Science:

• Oncology
• Immunology
• Clinical Medicine

Background:

• Immune checkpoint inhibitors (ICIs) like CTLA-4, PD-1, and PD-L1 inhibitors are crucial cancer therapies.
• While generally safe, ICIs can cause immune-related adverse events (irAEs) mimicking autoimmune diseases (AID).
• Patients with pre-existing AID are often excluded from trials, despite an increased cancer risk and need for treatment.

Purpose of the Study:

• To review existing evidence on the safety and activity of ICIs in cancer patients with pre-existing autoimmune diseases.
• To summarize ICI use based on primary tumor site and ICI type in this specific patient population.

Main Methods:

• Literature review of reported cases and studies involving ICIs in patients with pre-existing AID.
• Categorization of findings by primary tumor site and specific ICI agent (CTLA-4, PD-1, PD-L1 inhibitors).

Main Results:

• Limited retrospective evidence exists for ICI use in patients with certain pre-existing AID.
• ICI use in this population requires careful consideration due to potential irAEs and AID flares.
• Data is summarized to guide clinical decision-making.

Conclusions:

• Further research is needed to establish optimal ICI strategies for cancer patients with pre-existing AID.
• Balancing cancer treatment efficacy with autoimmune disease management is critical.
• Understanding ICI effects in AID patients is essential for improving oncologic outcomes.